Show simple item record

Authordc.contributor.authorLópez Villarroel, Néstor es_CL
Authordc.contributor.authorQuintero, Antonio es_CL
Authordc.contributor.authorCasanova, Patricia A. es_CL
Authordc.contributor.authorIbieta Hillerns, Carola es_CL
Authordc.contributor.authorBaelum, Vibeke es_CL
Authordc.contributor.authorLópez, Rodrigo 
Admission datedc.date.accessioned2012-05-10T15:39:08Z
Available datedc.date.available2012-05-10T15:39:08Z
Publication datedc.date.issued2012-03
Cita de ítemdc.identifier.citationJ Periodontol • March 2012 Volume 83 • Number 3es_CL
Identifierdc.identifier.otherdoi: 10.1902/jop.2011.110227
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/123443
Abstractdc.description.abstractBackground: The systemic inflammation in both metabolic syndrome (MetS) and periodontitis is a common denominator of the association of these conditions with higher risk of atherosclerosis. The current study investigates whether periodontal therapy may reduce systemic inflammation in patients with MetS and reduce cardiovascular risk. Methods: A parallel-arm, double-blind, randomized clinical trial of 1-year duration in patients with MetS and periodontitis was conducted. Participants were randomized to an experimental treatment group (ETG) (n = 82) that received plaque control and root planing plus amoxicillin andmetronidazole or to a control treatment group (CTG) (n = 83) that received plaque control instructions, supragingival scaling, and two placebos.Risk factors for cardiovascular disease were recorded; serum lipoprotein cholesterol, glucose, body mass index (BMI), C-reactive protein (CRP) and fibrinogen concentrations, and clinical periodontal parameters were assessed at baseline and every 3 months until 12 months after therapy. The primary and secondary outcomes were changes in CRP and fibrinogen levels, respectively. Results: The baselinepatients’ characteristics of both groupswere similar. No significant changes in lifestyle factors, frequency of hypertension, BMI, serum lipoprotein cholesterol, and glucose levels were observed during the study period. The periodontal parameters significantly improved in both groups 3 months after therapy (P = 0.0001) and remained lower than baseline up to 12 months. The improvement of periodontal status was significantly greater in the ETG (P = 0.0001). A multiple linear regression analysis, controlled for sex, smoking, hypertension, and extent of periodontitis, demonstrated that CRP levels decreased with time and that this reduction was significant at 9 (P = 0.024) and 12 (P = 0.001) months in both groups, without difference between the groups. Fibrinogen levels significantly decreased in the ETG at 6 and 12 months but not in the CTG. Conclusion: Reduction of periodontal inflammation eitherwith root planing and systemic antibiotics or with plaque control and subgingival scaling significantly reduces CRP levels after 9months in patients with MetS.es_CL
Patrocinadordc.description.sponsorshipThis work was supported by National Fund for Scientific and Technological Development Research Grant 1061070. The assistance of Dr. Benjamin Martinez (University Mayor, Santiago, Chile) in the randomization of patients and statistical analysis is gratefully acknowledged.es_CL
Lenguagedc.language.isoenes_CL
Keywordsdc.subjectcontrolled clinical triales_CL
Títulodc.titleEffects of Periodontal Therapy on Systemic Markers of Inflammation in Patients With Metabolic Syndrome: A Controlled Clinical Triales_CL
Document typedc.typeArtículo de revista


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record